496 related articles for article (PubMed ID: 23254158)
1. Clinical evaluation of PET image reconstruction using a spatial resolution model.
Andersen FL; Klausen TL; Loft A; Beyer T; Holm S
Eur J Radiol; 2013 May; 82(5):862-9. PubMed ID: 23254158
[TBL] [Abstract][Full Text] [Related]
2. Whole-body PET/MRI: the effect of bone attenuation during MR-based attenuation correction in oncology imaging.
Aznar MC; Sersar R; Saabye J; Ladefoged CN; Andersen FL; Rasmussen JH; Löfgren J; Beyer T
Eur J Radiol; 2014 Jul; 83(7):1177-1183. PubMed ID: 24780817
[TBL] [Abstract][Full Text] [Related]
3. Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors.
Sheikhbahaei S; Marcus C; Wray R; Rahmim A; Lodge MA; Subramaniam RM
Nucl Med Commun; 2016 Mar; 37(3):288-96. PubMed ID: 26650959
[TBL] [Abstract][Full Text] [Related]
4. Improvement in clinical evaluation of PET/CT images with high resolution algorithms.
Orlandini LC; Betti M; Fulcheri C; Dona M; Fisicaro D; Castagnoli A
Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):201-6. PubMed ID: 23486348
[TBL] [Abstract][Full Text] [Related]
5. A lesion detection observer study comparing 2-dimensional versus fully 3-dimensional whole-body PET imaging protocols.
Lartizien C; Kinahan PE; Comtat C
J Nucl Med; 2004 Apr; 45(4):714-23. PubMed ID: 15073270
[TBL] [Abstract][Full Text] [Related]
6. Impact of Point-Spread Function Modeling on PET Image Quality in Integrated PET/MR Hybrid Imaging.
Aklan B; Oehmigen M; Beiderwellen K; Ruhlmann M; Paulus DH; Jakoby BW; Ritt P; Quick HH
J Nucl Med; 2016 Jan; 57(1):78-84. PubMed ID: 26471697
[TBL] [Abstract][Full Text] [Related]
7. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
8.
Lasnon C; Majdoub M; Lavigne B; Do P; Madelaine J; Visvikis D; Hatt M; Aide N
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2324-2335. PubMed ID: 27325312
[TBL] [Abstract][Full Text] [Related]
9. Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging? - Variability induced by different SUV measurements and varying reconstruction methods.
Brendle C; Kupferschläger J; Nikolaou K; la Fougère C; Gatidis S; Pfannenberg C
Eur J Radiol; 2015 Jan; 84(1):158-162. PubMed ID: 25467224
[TBL] [Abstract][Full Text] [Related]
10. Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.
Lasnon C; Hicks RJ; Beauregard JM; Milner A; Paciencia M; Guizard AV; Bardet S; Gervais R; Lemoel G; Zalcman G; Aide N
Clin Nucl Med; 2012 Oct; 37(10):971-6. PubMed ID: 22899197
[TBL] [Abstract][Full Text] [Related]
11. Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET.
Akamatsu G; Mitsumoto K; Taniguchi T; Tsutsui Y; Baba S; Sasaki M
Eur J Radiol; 2014 Jan; 83(1):226-30. PubMed ID: 24144448
[TBL] [Abstract][Full Text] [Related]
12. Performance measurement of PSF modeling reconstruction (True X) on Siemens Biograph TruePoint TrueV PET/CT.
Lee YS; Kim JS; Kim KM; Kang JH; Lim SM; Kim HJ
Ann Nucl Med; 2014 May; 28(4):340-8. PubMed ID: 24504938
[TBL] [Abstract][Full Text] [Related]
13. Evaluating image reconstruction methods for tumor detection in 3-dimensional whole-body PET oncology imaging.
Lartizien C; Kinahan PE; Swensson R; Comtat C; Lin M; Villemagne V; Trébossen R
J Nucl Med; 2003 Feb; 44(2):276-90. PubMed ID: 12571221
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of whole-body oncologic PET with time-of-flight and point-spread function for the hybrid PET/MR system.
Shang K; Cui B; Ma J; Shuai D; Liang Z; Jansen F; Zhou Y; Lu J; Zhao G
Eur J Radiol; 2017 Aug; 93():70-75. PubMed ID: 28668434
[TBL] [Abstract][Full Text] [Related]
15. Defining optimal tracer activities in pediatric oncologic whole-body
Gatidis S; Schmidt H; la Fougère C; Nikolaou K; Schwenzer NF; Schäfer JF
Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2283-2289. PubMed ID: 27565153
[TBL] [Abstract][Full Text] [Related]
16. Validation of fast-RAMLA in clinical PET.
Sato H; Cho K; Fukushima Y; Shiiba M; Hakozaki K; Kiriyama T; Sakurai M; Kanaya K; Kumita S
Ann Nucl Med; 2008 Dec; 22(10):869-76. PubMed ID: 19142705
[TBL] [Abstract][Full Text] [Related]
17. Impact of time of flight and point spread function on quantitative parameters of lung lesions in
Huang K; Feng Y; Liang W; Li L
BMC Med Imaging; 2021 Nov; 21(1):169. PubMed ID: 34773998
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake values for [¹⁸F] FDG in normal organ tissues: comparison of whole-body PET/CT and PET/MRI.
Heusch P; Buchbender C; Beiderwellen K; Nensa F; Hartung-Knemeyer V; Lauenstein TC; Bockisch A; Forsting M; Antoch G; Heusner TA
Eur J Radiol; 2013 May; 82(5):870-6. PubMed ID: 23394765
[TBL] [Abstract][Full Text] [Related]
19. Comparison of 2-dimensional and 3-dimensional acquisition for 18F-FDG PET oncology studies performed on an LSO-based scanner.
Lodge MA; Badawi RD; Gilbert R; Dibos PE; Line BR
J Nucl Med; 2006 Jan; 47(1):23-31. PubMed ID: 16391183
[TBL] [Abstract][Full Text] [Related]
20. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
